White & Case Advises Takeda on Agreement to Divest Select Non-core European Assets to Cheplapharm for Approximately US$562 Million
1 min read
Global law firm White & Case LLP has advised Takeda Pharmaceutical Company Limited (Takeda) on an agreement to divest a portfolio of select non-core prescription pharmaceutical products sold in Europe and Canada to Cheplapharm for approximately US$562 million.
Takeda is a leading global biopharmaceutical company headquartered in Japan that is primarily focused on five business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience.
Cheplapharm is a specialty pharmaceutical company headquartered in Germany with a 25-year history of successfully acquiring, integrating and developing pharmaceutical products.
White & Case has previously advised Takeda on divestiture agreements covering select over-the-counter (OTC) and prescription pharmaceutical products in the Near East, Middle East and Africa (NEMEA) countries, Russia, Georgia, and a number of countries from within the Commonwealth of Independent States in 2019, and in Latin America, Europe and Asia-Pacific in 2020.
The White & Case team that advised on the transaction was led by partners Michael Immordino and Leonardo Graffi (both Milan and London) and included partners Philip Trillmich, Monica Holden, Nicholas Greenacre and Martin Forbes (all London), David Dreier (New York) and Axel Schulz (Brussels), counsel Isaac Tendler (New York), associates Heidi Blomqvist and Kate Russell (both London), Alessandro Piga (Milan), Ajita Shukla (Washington, DC), Tommaso Poli (Brussels) and Agmal Bahrami (Frankfurt) and lawyer Mariasole Maschio (Milan).
For more information, please speak to your local media contact.